U
Universe Pharmaceuticals Inc
NASDAQ:UPC
Universe Pharmaceuticals Inc
NASDAQ:UPC
Price:
2.34
USD
4.12%
Market Cap:
$1.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
U
|
Universe Pharmaceuticals Inc
NASDAQ:UPC
|
CN |
|
Nexteer Automotive Group Ltd
HKEX:1316
|
US |
|
Z
|
Zealand Pharma A/S
OTC:ZLDPF
|
DK |
|
G-Tec Jainx Education Ltd
NSE:GTECJAINX
|
IN |
|
Excelerate Energy Inc
NYSE:EE
|
US |
|
Batisoke Soke Cimento Sanayii TAS
IST:BSOKE.E
|
TR |
|
Shanta Gold Ltd
LSE:SHG
|
GG |
|
J
|
JMT Co Ltd
KOSDAQ:094970
|
KR |
|
Vmoto Ltd
ASX:VMT
|
AU |
|
Manchester United PLC
NYSE:MANU
|
UK |
|
Television Broadcasts Ltd
HKEX:511
|
HK |
|
WSP Global Inc
TSX:WSP
|
CA |
|
A
|
Astra Graphia Tbk PT
IDX:ASGR
|
ID |
|
T
|
Titijaya Land Bhd
KLSE:TITIJYA
|
MY |
|
Groupe Pizzorno Environnement SA
PAR:GPE
|
FR |
|
H
|
Hota Industrial Mfg. Co Ltd
TWSE:1536
|
TW |
|
F
|
Favelle Favco Bhd
KLSE:FFB
|
MY |
Multiples-Based Value
The Multiples-Based Value of one UPC stock under the Base Case scenario is hidden USD. Compared to the current market price of 2.34 USD, Universe Pharmaceuticals Inc is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
UPC Multiples-Based Value
LOCKED
Multiples Across Competitors
UPC Competitors Multiples
Universe Pharmaceuticals Inc Competitors
Universe Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
U
|
Universe Pharmaceuticals Inc
NASDAQ:UPC
|
1.3m USD | 0.1 | -0.4 | 10.4 | 8.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
847.5B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.1B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.3B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
